The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: An update

European Urology

Volumn 60, Issue 1, 2011, Pages 94-105

  Athanasopoulos, Anastasios ^a   Chapple, Christopher ^b   Fowler, Clare ^c   Gratzke, Christian ^d   Kaplan, Steven ^e   Stief, Christian ^d   Tubaro, Andrea ^f  

^a UNIVERSITY OF PATRAS   (Greece)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Alfa adrenoceptor antagonists; Alfa blockers; Anticholinergics; Antimuscarinics; Benign prostatic hyperplasia; Bladder outlet obstruction; Combination treatment; Overactive bladder; Systematic review; Systematic update

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; MUSCARINIC RECEPTOR BLOCKING AGENT; NAFTOPIDIL; OXYBUTYNIN; PROPIVERINE; SOLIFENACIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; TOLTERODINE; TROSPIUM CHLORIDE;

ARTICLE; BLADDER NECK STENOSIS; CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPOTENSION; MALE; MICTURITION; MONOTHERAPY; OVERACTIVE BLADDER; PRIORITY JOURNAL; QUALITY OF LIFE; SEX DIFFERENCE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; URINARY FREQUENCY; URINARY URGENCY; URINE FLOW RATE; XEROSTOMIA;

ADRENERGIC ALPHA-ANTAGONISTS; DRUG THERAPY, COMBINATION; HUMANS; MALE; MUSCARINIC ANTAGONISTS; URINARY BLADDER NECK OBSTRUCTION; URINARY BLADDER, OVERACTIVE;

EID: 79957935491     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.03.054     Document Type: Review

References (88)

1. W.M. Garraway, G.N. Collins, and R.J. Lee High prevalence of benign prostatic hypertrophy in the community Lancet 338 1991 469 471
2. A. Bertaccini, F. Vassallo, and F. Martino Symptoms, bothersomeness and quality of life in patients with LUTS suggestive of BPH Eur Urol 40 Suppl 1 2001 13 18 (Pubitemid 34701700)
3. T.J. Peters, J.L. Donovan, and H.E. Kay The International Continence Society "Benign Prostatic Hyperplasia" Study: the bothersomeness of urinary symptoms J Urol 157 1997 885 889 (Pubitemid 27066273)
4. P. Abrams, L. Cardozo, and M. Fall The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society Neurourol Urodyn 21 2002 167 178 (Pubitemid 34195211)
5. M.C. Michel, and C.R. Chapple Basic mechanisms of urgency: roles and benefits of pharmacotherapy World J Urol 27 2009 705 709
6. W.D. Steers Pathophysiology of overactive bladder and urge urinary incontinence Rev Urol 4 Suppl 4 2002 S7 18
7. F.M. Chu, and R. Dmochowski Pathophysiology of overactive bladder Amer J Med 119 2006 3S 8S (Pubitemid 43227967)
8. K.-E. Andersson Antimuscarinic mechanisms and the overactive detrusor: an update Eur Urol 59 2011 377 386
9. C.J. Fowler Bladder afferents and their role in the overactive bladder Urology 59 Suppl 1 2002 37 42 (Pubitemid 34462257)
10. B.T. Haylen, N. Chetty, and V. Logan Is sensory urgency part of the same spectrum of bladder dysfunction as detrusor overactivity? Int Urogynecol J Pelvic Floor Dysfunct 18 2007 123 128
11. J.G. Malone-Lee, and S. Al-Buheissi Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study BJU Int 103 2009 931 937
12. C.R. Chapple, and C.G. Roehrborn A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder Eur Urol 49 2006 651 659
13. H.J. Stoevelaar, C. Van de Beek, A.F. Casparie, J. McDonnel, and H.G. Nijs Treatment choice for benign prostatic hyperplasia: a matter of urologic preference? J Urol 161 1999 133 138 (Pubitemid 29422307)
14. N. Yoshimura Lower urinary tract symptoms (LUTS) and bladder afferent activity Neurourol Urodyn 26 Suppl 6 2007 908 913 (Pubitemid 47548227)
15. U. Mehnert, A. Reitz, S.A. Youssef, and B. Schurch Proof of principle: the effect of antimuscarinics on bladder filling sensations in healthy subjects - a placebo controlled double blind investigation using 4 and 8 mg tolterodine extended release Neurourol Urodyn 29 2010 464 469
16. K.-E. Andersson, and M. Yoshida Antimuscarinics and the overactive detrusor - which is the main mechanism of action? Eur Urol 43 2003 1 5 (Pubitemid 36134308)
17. P. Abrams, K.E. Andersson, and J.J. Buccafusco Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder Br J Pharmacol 148 2006 565 578 (Pubitemid 43993048)
18. A. Mattiasson, K.E. Andersson, A. Elbadawi, E. Morgan, and C. Sjögren Interaction between adrenergic and cholinergic nerve terminals in the urinary bladder of rabbit, cat and man J Urol 137 1987 1017 1019 (Pubitemid 17074930)
19. A.U. Trendelenburg, A. Meyer, J. Wess, and K. Starke Distinct mixtures of muscarinic receptor subtypes mediate inhibition of noradrenaline release in different mouse peripheral tissues, as studied with receptor knockout mice Br J Pharmacol 145 2005 1153 1159 (Pubitemid 43079988)
20. K.S. Lips, J. Wunsch, and S. Zarghooni Acetylcholine and molecular components of its synthesis and release machinery in the urothelium Eur Urol 51 2007 1042 1053 (Pubitemid 46281424)
21. M. Yoshida, K. Masunaga, and Y. Satoji Basic and clinical aspects of non-neuronal acetylcholine: expression of non-neuronal acetylcholine in urothelium and its clinical significance J Pharmacol Sci 106 2008 193 198 (Pubitemid 351366337)
22. P. Hedlund, T. Streng, T. Lee, and K.E. Andersson Effects of tolterodine on afferent neurotransmission in normal and resiniferatoxin treated conscious rats J Urol 178 2007 326 331 (Pubitemid 46898458)
23. C. Füllhase, R. Soler, C. Gratzke, M. Brodsky, G.J. Christ, and K.E. Andersson Spinal effects of the fesoterodine metabolite 5-hydroxymethyl tolterodine and/or doxazosin in rats with or without partial urethral obstruction J Urol 184 2010 783 789
24. L.P.W. Witte, C.R. Chapple, J.J.M.C.H. de la Rosette, and M.C. Michel Cholinergic innervation and muscarinic receptors in the human prostate Eur Urol 54 2008 326 334
25. J.N. Pennefather, W.A. Lau, F. Mitchelson, and S. Ventura The autonomic and sensory innervation of the smooth muscle of the prostate gland: a review of pharmacological and histological studies J Auton Pharmacol 20 2000 193 206 (Pubitemid 34211031)
26. S. Ventura, J. Pennefather, and F. Mitchelson Cholinergic innervation and function in the prostate gland Pharmacol Ther 94 2002 93 112 (Pubitemid 34615960)
27. W. Song, M. Yuan, and S. Zhao Variation of M3 muscarinic receptor expression in different prostate tissues and its significance Saudi Med J 30 2009 1010 1016
28. A. Athanasopoulos Antimuscarinics and bladder outlet obstruction: from a contraindication to an indication? Neurourol Urodyn 29 Suppl 1 2010 S46 50
29. S.A. Kaplan, C.G. Roehrborn, R. Dmochowski, E.S. Rovner, J.T. Wang, and Z. Guan Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia Urology 68 2006 328 332 (Pubitemid 44175507)
30. C.G. Roehrborn, P. Abrams, E.S. Rovner, S.A. Kaplan, S. Herschorn, and Z. Guan Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence BJU Int 97 2006 1003 1006
31. S.A. Kaplan, E.R. Goldfischer, W.D. Steers, M. Gittelman, M. Andoh, and S. Forero-Schwanhaeuser Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes Aging Male 13 2010 100 107
32. P. Ronchi, G.L. Gravina, G.P. Galatioto, A.M. Costa, O. Martella, and C. Vicentini Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity Neurourol Urodyn 28 2009 52 57
33. A. Hirayama, K. Fujimoto, and Y. Matsumoto Positive response to ice water test associated with high-grade bladder outlet obstruction in patients with benign prostatic hyperplasia Urology 62 2003 909 913 (Pubitemid 37421241)
34. H. Nishimatsou, Y. Homma, and K. Kawabe Efficacy of treatment with propiverine hydrochloride in patients on lower urinary tract function - BUP-4 tablets special study group II Jpn J Urol Surg 12 1999 857 867
35. P. Abrams, S. Kaplan, H.J. De Koning Gans, and R. Millard Safety and tolerability of tolderodine for the treatment of overactive bladder in men with bladder outlet obstruction J Urol 175 2006 999 1004 (Pubitemid 43200054)
36. S.A. Kaplan, K. Walmsley, and A.E. Te Tolderodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia J Urol 174 2005 2273 2276
37. T. Yokoyama, K. Uematsu, T. Watanabe, K. Sasaki, H. Kumon, and A. Nagai Okayama Urological Research Group. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study Scand J Urol Nephrol 43 2009 307 314
38. S.A. Kaplan, C.G. Roehrborn, E.S. Rovner, M. Carisson, T. Bavendam, and Z. Guan Tolderodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial JAMA 296 2006 2319 2328 (Pubitemid 44749359)
39. L.A.G. Rodriguez, M.E.M. Merino, E.L.M. Gonzales, and C.G. Roehrborn The Health Improvement Network (THIN) database: focused safety study of acute urinary retention (AUR) in men Eur Urol Suppl 8 2009 236
40. C. Sung Yong, S. Hyun Dong, C. In Rae, P. Seok San, S. Ki Hak, and C. Jin Soen The risk factors increasing post void residual urine volume after long term anticholinergics therapy over 1 year in patients with benign prostatic hyperplasia accompanied with overactive bladder Eur Urol Suppl 8 2009 237
41. D.E. Chung, and S.A. Kaplan Current role for combination therapy in male LUTS Arch Esp Urol 63 2010 323 332
42. C.R. Chapple, and D. Smith The pathophysiological changes in the bladder obstructed by benign prostatic hyperplasia Br J Urol 73 1994 117 123 (Pubitemid 24057655)
43. A. Athanasopoulos, K. Gyftopoulos, K. Giannitsas, J. Fisfis, P. Perimenis, and G. Barbalias Combination treatment with an a-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized controlled study J Urol 169 2003 2253 2256 (Pubitemid 36576764)
44. H. Saito, T. Yamada, and H. Oshima A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and/or urinary incontinence Jpn J Urol Surg 8 1999 525 536
45. A.G. Athanasopoulos, and P.S. Perimenis Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder BJU Int 95 2005 1117 1118 (Pubitemid 40655721)
46. K.S. Lee, M.S. Choo, and D.Y. Kim Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign obstruction: a prospective, randomized, controlled multicenter study J Urol 174 2005 1334 1338
47. E.S. Rovner, K. Kreder, and D.O. Sussman Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms J Urol 180 2008 1034 1041
48. S.A. Kaplan, C.G. Roehrborn, M. Chancellor, M. Carlsson, T. Bavendam, and Z. Guan Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score BJU Int 102 2008 1133 1139
49. N.K. Mohanty, A. Kumar, M. Jain, S. Prakash, and R.P. Arora Efficacy and safety of an alpha-blocker with and without anticholinergic agent in the management of lower urinary tract symptoms with detrusor overactivity UroToday Int J 2009 2 doi:10.3834/uij.1944-5784.2009.12.02
50. O. Maruyama, Y. Kawachi, and K. Hanazawa Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: a prospective randomized controlled study Int J Urol 13 2006 1280 1285 (Pubitemid 44453693)
51. Y. Yang, X.F. Zhao, and H.Z. Li Efficacy and safety of combined therapy with terazosin and tolterodine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study Chin Med J (Engl) 120 2007 370 374 (Pubitemid 46488346)
52. I.S. Kang, Z.H. Sung, and B.L. Jong The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms Korean J Urol 50 2009 1078 1082
53. J.Y. Lee, H.W. Kim, S.J. Lee, J.S. Koh, H.J. Suh, and M.B. Chancellor Comparison of doxazosin with or without tolderodine in men with symptomatic bladder outlet obstruction and an overactive bladder BJU Int 94 2004 817 820 (Pubitemid 39472476)
54. S.A. MacDiarmid, K.M. Peters, and A. Chen Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study Mayo Clin Proc 83 2008 1002 1010
55. C. Chapple, S. Herschorn, P. Abrams, F. Sun, M. Brodsky, and Z. Guan Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with α-blockers Eur Urol 56 2009 534 543
56. S.A. Kaplan, K. McCammon, R. Fincher, A. Fakhoury, and W. He Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency J Urol 182 2009 2825 2830
57. A. Wiedemann, G. Neumann, C. Neumeister, W. Kusche, and U. Schwantes Efficacy and tolerability of add-on trospium chloride in patients with benign prostate syndrome and overactive bladder: a non-interventional trial showing use of flexible dosing UroToday Int J 2009 2 doi:10.3834/uij.1944-5784.2009.04.02
58. M. Aldemir, K. Aras, D. Dehni, and O. Kayigil Prospective comparison of two treatment modalities in benign prostate hyperplasia: alpha-blocker alone vs. alpha-blocker plus anticholinergic combination Turkiye Klinikleri J Med Sci 30 2010 539 543
59. Suzuki Y, Takasaka S, Kishimoto K, et al. Combination treatment with an alpha1-blocker plus an anticholinergic for the patients with suspected bladder outlet obstruction (BOO) concomitant with over-active bladder (OAB). Abstract presented at: International Continence Society Annual Meeting; August 25-27, 2004; Paris, France.
60. Lim E, Chia SJ. Combination therapy using alpha-blocker and antimuscarinic drugs in men with lower urinary tract symptoms suggestive of bladder outlet obstruction and an overactive bladder: is it safe and efficacious? Abstract presented at: International Continence Society Annual Meeting; August 28-September 2, 2005; Montreal, Canada.
61. Kaplan SA, Zoltan E, Te AE. Safety and efficacy of tolterodine, solifenacin, and darifenacin in men with lower urinary tract symptoms (LUTS) on alpha-blockers with persistent overactive bladder symptoms. Abstract presented at: American Urological Association Annual Meeting; May 17-22, 2008; Orlando, FL, USA.
62. D.E. Chung, A.E. Te, D.R. Staskin, and S.A. Kaplan Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams Urology 75 2010 1144 1148
63. A. Athanasopoulos, D. Mitropoulos, K. Giannitsas, and P. Perimenis Safety of anticholinergics in patients with benign prostatic hyperplasia Expert Opin Drug Saf 7 2008 473 479
64. C. Füllhase, R. Soler, C. Gratzke, M. Brodsky, G.J. Christ, and K.E. Andersson Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction BJU Int 106 2010 287 293
65. G. Conde-Santos, M. Rebassa-Llull, and L. Soriano-Burrull Study of safety and urodynamic characterization of treatment with tamsulosin, tolderodine and tamsulosin plus tolderodine, in men with LUTS Eur Urol Suppl 8 2009 237
66. G.G. Kay, and U. Ebinger Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin Int J Clin Pract 62 2008 1641 1642
67. Chapple C, Billington A, Jeachins P, et al. The management of lower urinary tract symptoms in men. Report of National Institute for Health and Clinical Excellence (NICE). NICE Web site. http://www.nice.org.uk/nicemedia/ live/12984/48556/48556.pdf.
68. M.J. Speakman Editorial comment on: tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with α-blockers Eur Urol 56 2009 542 543
69. R. Dmochowski Editorial comment on: tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with α-blockers Eur Urol 56 2009 542
70. C.G. Roehrborn, S.A. Kaplan, J.S. Jones, J.T. Wang, T. Bavendam, and Z. Guan Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size Eur Urol 55 2009 472 481
71. C.G. Roehrborn, S.A. Kaplan, S.R. Kraus, J.T. Wang, T. Bavendam, and Z. Guan Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB Urology 72 2008 1061 1067
72. C.R. Chapple, S. Herschorn, P. Abrams, J.T. Wang, M. Brodsky, and Z. Guan Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an alpha-blocker: effect of baseline prostate-specific antigen concentration BJU Int 106 2010 1332 1338
73. S.A. Kaplan, and R.R. Gonzalez Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms Rev Urol 9 2007 73 77
74. C. Wang Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia Curr Opin Urol 20 2010 49 54
75. F.A. Giuliano, J. Lamb, A. Crossland, S. Haughie, P. Ellis, and N.A. Tamimi A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder BJU Int 106 2010 666 673
76. J. Gillespie, V. Guilloteau, C. Korstanje, P. Lluel, and S. Palea Differences in the actions of the M3-antagonist tolterodine and the beta 3 adrenoceptor agonist mirabegron on non-voiding activity in rats with partial outflow obstruction [abstract] Int Urogynecol J 21 Suppl 1 2010 S292 S293
77. J.K. Badawi, T. Seja, and H. Uecelehan Relaxation of human detrusor muscle by selective beta-2 and beta-3 agonists and endogenous catecholamines Urology 69 2007 785 790 (Pubitemid 46574943)
78. C.R. Chapple, O. Yamaguchi, and A. Ridder Clinical proof of concept study (BLOSSOM) shows novel β3 adrenoreceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder Eur Urol Suppl 7 2008 239
79. C. Chapple, J.J. Wyndaele, P. Van Kerrebroeck, P. Radziszewski, V. Dvorak, and P. Boerrigter Dose-ranging study of once-daily mirabegron (YM178), a novel selective β3-adrenoreceptor agonist, with overactive bladder (OAB) Eur Urol Suppl 9 2010 249
80. T. Blake-James, A. Rashidian, Y. Ikeda, and M. Emberton The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis BIU Int 99 2006 85 96
81. G. Novara, A. Galfano, V. Ficarra, and W. Artibani Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review Eur Urol 50 2006 675 683 (Pubitemid 44332687)
82. A. Athanasopoulos, and P. Perimenis Efficacy of the combination of an alpha1-blocker with an anticholinergic in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction Expert Opin Pharmacother 6 2005 2429 2433 (Pubitemid 41701045)
83. M.R. Ruggieri, A.S. Braverman, and M.A. Pontari Combined use of alpha-adrenergic and muscarinic antagonist for the treatment of voiding dysfunction J Urol 174 2005 1743 1748 (Pubitemid 41546925)
84. S.A. MacDiarmid Combination antimuscarinics and alpha-blockers for benign prostatic hyperplasia Curr Urol Rep 9 2008 265 271
85. J.Y. Lee, D.K. Kim, and M.B. Chancellor When to use antimuscarinics in men who have lower urinary tract symptoms Urol Clin North Am 33 2006 531 537 (Pubitemid 44444929)
86. R. Dmochowski Antimuscarinic therapy in men with lower urinary tract symptoms: what is the evidence? Curr Urol Rep 7 2006 462 467 (Pubitemid 44663238)
87. J.M. Reynard Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents? Curr Opin Urol 14 2004 13 16 (Pubitemid 39186207)
88. C. Chapple Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia Curr Opin Urol 20 2010 43 48